Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.
Thirty inpatients with evidence of tardive dyskinesia secondary to antipsychotic medications participated in this double-blind, controlled, randomized study comparing reserpine, alpha-methyldopa and placebo. Reserpine at doses of 0.75--1.5 mg daily, or alpha-methyldopa at doses of 750--1,500 mg daily, produced a statistically significant improvement in tardive dyskinesia symptomatology compared to the results obtained with placebo.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006801:Humans; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy; D012110:Reserpine / Q000627:therapeutic use*
D008750:Methyldopa; D012110:Reserpine